

L'acquisto di dispositivi medici alla luce del nuovo regolamento: modalità applicative, criticità, soluzioni

# L'esperienza di un Operatore Economico



6 aprile 2023 Fulvia Meroni, Regulatory Affairs Manager, Medtronic Italia S.p.A.

### Today

- Medtronic and EU MDR
- How we organized for MDR ?
- Who are we working with ?
- What is working well ?
- What are our main challenges ?
- Concluding remarks



In the past year, Medtronic therapies improved the lives of 76 million+ people. That's **two people every second** of every hour of every day – and counting.

### Engineering the extraordinary

150+

80 manufacturing sites

239 clinical trials last year

12.9K+

and engineers

### 38 labs and research

95K+

employees

\$2.7B in R&D investments last year

development sites

49,967

active patent matters

### Our dedication to transforming lives starts here



#### Beyond products: Integrated health solutions (IHS)

We partner with hospital management and medical leaders to transform care pathways and clinical operations, with a shared goal of:

- Improving efficiency and outcomes
- Increasing patient and staff satisfaction
- Optimizing cost

With our extensive experience across and within regions, we provide proven and highly effective solutions that can be quickly tailored to providers' specific needs and generate value now – and for the future.

### Positive impact on complex and challenging conditions

70+

## 2

**conditions** in the human body treated with our therapies

**people every second** have their lives improved – and counting

#### Public-private partnerships

Increasing patient access in multiple communities aligns with the core of our Mission. These publicprivate partnerships – with outcome-oriented business models – create mutual benefits by making the most of Medtronic skills, expertise, and assets through the appropriate transfer of risk. They drive our globalization strategy and actively contribute to the international push for universal health coverage. With jointly defined objectives, they address health system challenges efficiently by increasing access to therapy innovation, raising quality, and delivering improved outcomes.



Learn more at Medtronic.com


©2022 Medtronic. Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. UC202206905a EN

### Our life-transforming technologies treat more than **70 conditions**





Our therapies and solutions span four portfolios to treat more than 70 conditions in the human body



### **Medtronic**

# Today, we are engineering the extraordinary to treat more than 70 conditions.

### Cardiovascular

#### **Cardiac Ablation Solutions**

Persistent atrial fibrillation First line indication paroxysmal atrial fibrillation Non-atrial fibrillation arrythmias

#### **Cardiac Surgery**

Beating heart bypass surgery Perfusion Surgical revascularization Extracorporeal life support Surgical valves for aortic, mitral, and tricuspid valve diseases

#### **Mechanical Circulatory Support**

#### Cardiac Rhythm Management

Bradycardia Tachycardia Sudden Cardiac Arrest (SCA) Arrhythmia diagnostics Infection control for implanted devices Remote monitoring Heart failure Cardiac resynchronization therapy

#### **Peripheral Vascular Health**

- Carotid artery disease
- Chronic venous insufficiency
- End-stage renal disease
- Peripheral artery disease
- Deep venous disease

#### **Structural Heart and Aortic**

- Aortic valve disease
- Mitral valve disease
- Pulmonary valve disease
- Tricuspid valve disease
- Aortic abdominal aneurism (AAA)
- Thoracic aortic aneurysm (TAA)

#### **Coronary & Renal Denervation**

- Hypertension
- Coronary artery disease

### Cardiovascular Diagnostics and Services

Stroke

.

- Syncope
- Suspected atrial fibrillation
- Atrial fibrillation management
- Cardiac arrythmias

### **Medical Surgical**

#### Gastrointestinal

- Colorectal polyps
- GI bleeding
- GERD

- Barrett's esophagus
- Liver tumors
- Motility disorders
- Hemorrhoids

#### **Patient Monitoring**

- Blood oxygen management
- Respiratory compromise
- Perioperative complications

#### **Surgical Robotics**

- Urologic
- Gynecologic
- General surgery (alimentary canal & abdominal)

#### **Renal Care Solutions**

- Acute kidney injury
- Chronic kidney disease
- End stage renal disease

#### **Respiratory Interventions**

Respiratory failure

#### Surgical Innovations

- General Surgery
- Colorectal conditions
- Gynecologic conditions
- Obesity & metabolic health
- Hernia repair
- Wound management
- Lung health

#### **Medtronic Care Management Services**



#### **Cranial & Spinal Technologies**

- Cranial and orthopedic trauma
- Neurological disorders
- Neuro tumors
- Hydrocephalus
- Spinal and cranial tumors
- Spine trauma and deformity
- Scoliosis
- Degenerative diseases
- Herniated/bulging discs
- Spondylolisthesis
- Spinal stenosis

#### **Pelvic Health**

- Overactive bladder
- Non-obstructive urinary retention
  - Fecal incontinence

#### Neurovascular

- Acute ischemic stroke
- Hemorrhagic stroke

#### Neuromodulation


- Parkinson's disease
- Epilepsy
- Essential tremor
- Cancer pain
- Chronic pain
- Severe spasticity
- Vertebral compression fractures

#### Ear/Nose/Throat

- Chronic rhinosinusitis (CRS)
- Head and neck cancer
- Skull base tumors
  - Medtronic

- Diabetes
- Type 1 diabetes
- Type 2 diabetes

### How we organized for EU MDR?




**Medtronic** 

### Who are we working with ?

- Work with **10 Notified Bodies**
- Actively filing under MDR since 2019
- Four Notified Bodies cover 90% of our portfolio
- **Time-to-certification varies** across all device categories & Notified Bodies
- Submission Files are **10x** volume vs MDD
- **Volume** of questions much **higher** than previous experience under MDD

# Breakdown of the Notified Body deficiency types for a typical OU





### What is working well for us ?



**Lesson Learned:** Pilot Submissions & Sharing of best practices within the organisation



**Interactive:** Regular interactions with Notified Bodies



Enhanced **Submission tracking** and status reporting/visibility



### **Scheduled reviews:**

Notified Bodies schedule reviews at start and through deficiency cycles.



### What are our main challenges?



Notified Body Capacity

**Predictability** of review process/timelines

Medicinal Reviews - capacity & review times

**Maintaining outside EU registrations -** Historical reliance on CE Mark

Minimizing Supply Disruptions

Impact Innovation in Europe



### Conclusions

- We want to see MDR done
- We are seeing progress but significant distance to go
- We need to keep Patient Access to the forefront
- Patients deserve access to what they currently have today at a minimum...**and** the latest innovations.
- We need predictability in the certification process











Medtronic